GONORRHEA VACCINE
nOMV vaccine aims to prevent Neisseria gonorrhoeae infections

AdJane is developing a vaccine candidate to prevent infections caused by Neisseria gonorrhoeae (N. gonorrhoeae).AdJane is a clinical-stage vaccine platform company based in the Netherlands that utilizes its native Outer Membrane Vesicle (nOMV) platform to address antimicrobial resistance, pandemic preparedness, and global health challenges.

N. gonorrhoeae causes gonorrhea, one of the most commonly reported sexually transmitted bacterial infections responsible for over 80 million new infections annually. The disease can lead to severe complications including pelvic inflammatory disease, infertility, and an increased risk of contracting HIV, while many infections go undiagnosed due to the absence of symptoms.

Furthermore, N. gonorrhoeae does not induce durable natural immunity, resulting in frequent reinfections and repeatedcourses of antibiotic treatment. The cycle of reinfection and antibiotic exposure has contributed to escalatingantimicrobial resistance.

AdJane’s nOMV platform – building on a completed Phase I clinical trial that demonstrated a favorable safety profile in humans – is being applied to gonorrhea through a heterologous approach. This strategy combines a broad, platform-driven antigenic background with the targeted expression of multiple highly conserved gonococcal antigens to elicit a targeted, broad-spectrum immune response to N. gonorrhoeae.

Current Development Stage: Hit-to-lead

CARB-X Investment: US$2.6 million

Initial CARB-X Investment Date: April 28, 2026